ANAVEX 2-73

Drug Profile

ANAVEX 2-73

Alternative Names: ANAVEX-2-73

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anavex Life Sciences
  • Developer ABX-CRO; Anavex Life Sciences; The Michael J. Fox Foundation for Parkinsons Research
  • Class Antidementias; Dimethylamines; Furans; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists; Muscarinic M1 receptor agonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy; Rett syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Parkinson's disease
  • Phase I Cognition disorders; Epilepsy; Rett syndrome
  • Preclinical Angelman syndrome; Anxiety disorders; Autistic disorder; Fragile X syndrome; Multiple sclerosis
  • No development reported Amyotrophic lateral sclerosis; Stroke

Most Recent Events

  • 09 Jul 2018 Spanish Agency for Medicinal Products and Medical Devices (AEMPS) approves clinical trial application for phase II trial of ANAVEX 2-73 in Parkinson’s Disease (PDD) Dementia
  • 04 Jul 2018 Phase-II clinical trials in Parkinson's disease in Spain (PO) (EudraCT2017-004335-36)
  • 03 Jul 2018 Australian Human Research Ethics Committee grants approval to initiate phase IIb/III trial in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top